2-aminoethoxyacetic acid derivatives and their use

• US 7,932,278 B2
• Filed: 09/14/2006
• Issued: 04/26/2011
• Est. Priority Date: 09/23/2005
• Status: Active Grant

• Current Assignee: Bayer Intellectual Property GmbH (Bayer AG)
• Original Assignee: Bayer Schering Pharma AG (Bayer AG)
• Inventors: Thomas, Christian R., Perzborn, Elisabeth, Röhrig, Susanne
• Primary Examiner(s): Saeed; Kamal A
• Application Number:
  US11/992,396
• Publication Number:
  US 20090036504A1
• Time in Patent Office: 1,685 Days
• Field of Search: None
• US Class Current: 514/376
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 7/02 Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• CPC Class Codes: C07D 413/12 linked by a chain containing hetero atoms as chain links

Abstract

The present application relates to novel 2-aminoethoxyacetic acid derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular thromboembolic disorders.

Claims

1. An isolated compound of the formula (I)

2. The isolated compound of the formula (I) as claimed in claim 1 in which R is hydrogen, isobutylaminocarbonyl or 5-chloro-2-thienylcarbonyl, or a salt thereof.

3. The isolated compound of the formula (I) as claimed in claim 1 having the structure below:

4. A process for preparing the compound of claim 1, characterized in that the compound of the formula (II)

5. A pharmaceutical composition comprising the compound of claim 1 in combination with an inert non-toxic, pharmaceutically suitable auxiliary.

6. A pharmaceutical composition comprising the compound in claim 1 in combination with a further active compound.

7. A method for the treatment of thromboembolic disorders in humans and animals, which comprises using administering an anticoagulatory effective amount of at least one compound of claim 1.

8. A method for stabilizing a blood sample in vitro, characterized in that an anticoagulatory effective amount of the compound of claim 1 is added.